Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2017020803
pages 389-401

Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction

Yu Yang
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
Catherine R. Miller
Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA
Antonio Lopez-Beltran
Department of Pathology and Surgery, Faculty of Medicine, Cordoba, Spain and Champalimaud Clinical Center, Lisbon, Portugal
Rodolfo Montironi
Institute of Pathological Anatomy and Histopathology Polytechnic University of the Marche Region (Ancona) and United Hospitals Ancona, Italy
Monica Cheng
Departments of Pathology, Indiana University School of Medicine, Indianapolis, USA
Shaobo Zhang
Departments of Pathology, Indiana University School of Medicine, Indianapolis, USA
Michael O. Koch
Department of Urology, Indiana University School of Medicine, Indianapolis, USA
Hristos Z. Kaimakliotis
Department of Urology, Indiana University School of Medicine, Indianapolis, USA
Liang Cheng
Departments of Pathology, Indiana University School of Medicine, Indianapolis, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, USA

ABSTRACT

In this review, we discuss the types of liquid biopsies currently available, and their recent and potential clinical applications, especially as they relate to the detection of molecular biomarkers of bladder cancer. The advances in research using high-throughput next-generation genomic techniques have identified a number of promising molecular biomarkers of bladder urothelial carcinoma. Liquid biopsy has recently received enormous attention as a potential tool for real-time monitoring of disease status in cancer patients, and genomic profiles are reported to closely match those of corresponding tumors. It is noninvasive and easily repeated, and allows monitoring during treatment and detection of different genomic alterations that are potentially accessible to targeted therapy or are associated with treatment resistance in bladder cancer patients. Moreover, liquid biopsy is a tool that allows rapid access to biomarker assessment in patients for whom solid biopsies are not available. Liquid biopsy will be widely applied to daily clinical practice and serve as an important tool for the screening, surveillance, prediction of outcomes, and selection of effective targeted therapies in bladder carcinoma.